Literature DB >> 12116851

Antibody responses in parvovirus B19 infected patients.

Susanne Modrow1, Simone Dorsch.   

Abstract

Parvovirus B19 is the causative agent of erythema infectiosum. In addition, the infection may be associated with other disease manifestations: anemia and aplastic crisis, thrombo- or granulocytopenies; spontaneous abortion or hydrops fetalis in pregnant women; acute and chronic arthritis in adults and children, myocarditis and hepatitis. Both acute and persistent courses of B19-infections have been reported. All patients develop IgG against the capsid proteins VP1 and VP2, the majority of virus neutralizing antibodies that offer life-long protection against reinfections are directed against the VP1-unique region. IgM is mainly directed against VP2-specific epitopes. These antibodies may be present for only a rather short period of two to ten weeks after acute infection. IgG-antibodies against the nonstructural protein NS1 are preferentially found in patients which are unable to eliminate the virus and develop persisting viremia or virus persistence in distinct organs, e.g. synovial fluid, liver, bone marrow.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116851     DOI: 10.1016/s0369-8114(02)00302-4

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  16 in total

1.  Analysis of nucleotide sequences of human parvovirus B19 genome reveals two different modes of evolution, a gradual alteration and a sudden replacement: a retrospective study in Sapporo, Japan, from 1980 to 2008.

Authors:  Masashi Suzuki; Yuko Yoto; Aki Ishikawa; Hiroyuki Tsutsumi
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

2.  Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans.

Authors:  Oscar Norbeck; Adiba Isa; Christoph Pöhlmann; Kristina Broliden; Victoria Kasprowicz; Paul Bowness; Paul Klenerman; Thomas Tolfvenstam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Prevalence of parvovirus B19-specific antibodies and of viral DNA in patients with endogenous uveitis.

Authors:  Carsten Heinz; Annelie Plentz; Dirk Bauer; Arnd Heiligenhaus; Susanne Modrow
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

4.  Republished: pathogenesis and diagnosis of myocarditis.

Authors:  Chantal Elamm; Delisa Fairweather; Leslie T Cooper
Journal:  Postgrad Med J       Date:  2012-09       Impact factor: 2.401

5.  Phylogenetic evidence for the rapid evolution of human B19 erythrovirus.

Authors:  Laura A Shackelton; Edward C Holmes
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Parvovirus B19 genotype specific amino acid substitution in NS1 reduces the protein's cytotoxicity in culture.

Authors:  Violetta Kivovich; Leona Gilbert; Matti Vuento; Stanley J Naides
Journal:  Int J Med Sci       Date:  2010-05-25       Impact factor: 3.738

7.  Evaluation of the diagnostic work-up in children with myocarditis and idiopathic dilated cardiomyopathy.

Authors:  S L den Boer; R P J Meijer; G G van Iperen; A D J Ten Harkel; G J du Marchie Sarvaas; B Straver; L A J Rammeloo; R B Tanke; J J A van Kampen; M Dalinghaus
Journal:  Pediatr Cardiol       Date:  2014-09-07       Impact factor: 1.655

8.  A Parsonage-Turner Syndrome secondary to Parvovirus B19 infection.

Authors:  Flavio Mozzani; Noemi Giuliana Marino; Andrea Becciolini; Eleonora Di Donato; Alarico Ariani; Daniele Santilli
Journal:  Acta Biomed       Date:  2021-04-30

9.  Effects of human parvovirus B19 VP1 unique region protein on macrophage responses.

Authors:  Bor-Show Tzang; Chun-Ching Chiu; Chun-Chou Tsai; Yi-Ju Lee; I-Jung Lu; Jing-Yu Shi; Tsai-Ching Hsu
Journal:  J Biomed Sci       Date:  2009-01-24       Impact factor: 8.410

10.  Parvovirus B19-related chronic monoarthritis: immunohistochemical detection of virus-positive lymphocytes within the synovial tissue compartment: two reported cases.

Authors:  Carsten Lennerz; Henning Madry; Sandra Ehlhardt; Thorsten Venzke; Klaus D Zang; Yasmin Mehraein
Journal:  Clin Rheumatol       Date:  2003-11-05       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.